

H 30  
27. A medicament for reducing atherosclerotic plaque formation at sites of endothelial damage in humans through the reduction of cholesterol incorporation into the endothelium comprising:

- rule 126  
(a) aspirin orally administered in a dose effective to block prostaglandin function in platelets sufficiently to reduce the ability of platelets to go to the site of the endothelial damage and recruit other cells to assist in thrombosis; and  
(b) a vitamin orally administered in a dose effective to reduce the migration of cholesterol into the endothelium, wherein said multivitamin comprises at least one vitamin from the group including niacin, vitamin C, vitamin E, and vitamin B<sub>6</sub>.

rule 126 31/28. A medicament as defined in claim 27, wherein said multivitamin contains between about 10 percent and 200 percent of the United States Recommended Daily Allowance of at least one vitamin selected from the group consisting of vitamin B<sub>6</sub>, vitamin C, vitamin E, and niacin.

In the Specification:

Please include the following sentence at the beginning of the specification.

This application is a continuation application of Serial No. 08/071,052 filed on June 4, 1993, now abandoned.

REMARKS

Claims 27 - 29 are rejected under 35 U.S.C. 103 as being obvious over Hanneckens (5,871,766) in that it is asserted to teach the composition of beta-carotene and aspirin.

While it is not explicitly asserted in the Office Action, it is understood that the Examiner is applying the reference to the present application in that beta-carotene has vitamin A activity. The foregoing amendments remove vitamin A from the claims 27 and 28.

RECEIVED  
JAN 17 2002  
OFFICE OF PETITIONS